All In Biotech

Drug Trial Radar · NCT07363460

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HSK39297 Tablets in Patients With Lupus Nephritis

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

Nov 5, 2027

Study completion Jul 6, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis

Conditions

  • Lupus Nephritis (LN)

Interventions

  • HSK39297 200mgQDDrug

    once daily, oral administration of HSK39297 tablets 200mg from Day 1 to Week 52.

  • HSK39297 300mgQDDrug

    once daily, oral administration of HSK39297 tablets 300mg from Day 1 to Week 52.

  • PlaceboDrug

    once daily, oral administration of placebo from Day 1 to Week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of 24h-UPCR compared to BaselineTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.